Pupil Dilation for Treatment of IFIS



Status:Recruiting
Healthy:No
Age Range:18 - 100
Updated:2/1/2019
Start Date:January 4, 2019
End Date:January 1, 2020
Contact:Cristos Ifantides, MD
Email:cristos.ifantides@ucdenver.edy
Phone:303-602-5423

Use our guide to learn which trials are right for you!

Enhanced Pupil Dilation in Patients Taking Alpha-Blockers for Potential Treatment of Intraoperative Floppy Iris Syndrome

A novel intervention for targeting the treatment of Intraoperative Floppy Iris Syndrome.

This study explores the effects that medication can have on increasing pupil dilation. Pupil
dilation size is important for operative eye procedures. Decreased pupil size is related to
increased complication risks in eye surgery. By exploring novel pupil dilation techniques,
there is a potential to counteract the effects of poor pupil dilation that is caused by
medications such as alpha-blockers. Intraoperative floppy iris syndrome is a syndrome
characterized by a floppy iris (IFIS) and poor pupil dilation during surgery that is caused
by BPH medications. This study evaluates treatment methods targeting IFIS.

Inclusion Criteria:

1. Adults (18 years old or greater) 3. History of having taken, or currently taking any
systemic alpha blocker 2. Ability to consent themselves 3. Ability to apply eye drops
themselves TID for 7 days

Exclusion Criteria:

1. Subjects with untreated hypertension or baseline BP >160

2. Subjects with Thyrotoxicosis

3. Pregnant women or women trying to conceive

4. Prisoners

5. Inability consent

6. Subjects with anatomical narrow angles or who have never had a dilated eye exam

7. Subjects currently prescribed brimonidine tartrate for glaucoma

8. Subjects who take topical or systemic alpha agonists

9. Patients who take monoamine oxidase (MAO) inhibitors

10. Patients with known severe cardiovascular disease
We found this trial at
1
site
Denver, Colorado 80204
Phone: 303-602-5423
?
mi
from
Denver, CO
Click here to add this to my saved trials